Abstract |
Many locally advanced nasopharyngeal carcinoma patients develop local recurrence or distant metastasis. Our retrospective real-world study aims to evaluate the efficacy and safety of curative sequential approach with induction chemotherapy followed by concurrent chemoradiation + nimotuzumab as first-line therapy in advanced nasopharyngeal carcinoma. From 2015 to 2021, the clinic data of 117 patients with advanced nasopharyngeal carcinoma (stage III-IV a) who were treated in the Affiliated Hospital of Guangdong Medical University were retrospectively reviewed. Fifty-four patients in observation group received taxanes, cisplatin, and 5-fluorouracil/ taxanes and cisplatin induction chemotherapy and nimotuzumab (200 mg, weekly) combined with concurrent chemo- radiotherapy ( cisplatin: 40 mg/m2 weekly; intensity-modulated radiation therapy); 63 patients in control group received same therapy without nimotuzumab. There was no significant difference in patients' characteristic baseline between 2 groups (P > .05). The complete response rate and objective response rate of the observational group was significantly higher than control group (46.30% vs 17.64%, P = .01; 96.30% vs 82.54%, P = .02). The median follow-up time was 24.77 (3.53-65.97) months. Both of the median progress free survival time and overall survival time were not reached. The 5-year progression-free survival rate of observation group was greater than control group (84.40% vs 63.70%, hazard ratios 0.365, 95% confidence intervals 0.147-0.909, P = .03). The 5-year overall survival rate of observation group and control group were 91.70% and 84.60%, respectively (P = .20). None of the patients withdrew from the study due to adverse events. Nimotuzumab combined with concurrent chemoradiotherapy as first-line therapy in advanced nasopharyngeal carcinoma can improve objective response rate and 5-year progress free survival rate with good safety profile.
|
Authors | Danxian Jiang, Jinxin Cao, Linying Guo, Yonghua Chen, Ge Yuan, Jing Huang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 102
Issue 4
Pg. e32732
(Jan 27 2023)
ISSN: 1536-5964 [Electronic] United States |
PMID | 36705354
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. |
Chemical References |
- nimotuzumab
- Cisplatin
- Taxoids
|
Topics |
- Humans
- Nasopharyngeal Carcinoma
(drug therapy)
- Induction Chemotherapy
- Retrospective Studies
- Cisplatin
(therapeutic use)
- Nasopharyngeal Neoplasms
(pathology)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Neoplasm Staging
- Chemoradiotherapy
(adverse effects)
- Taxoids
(therapeutic use)
|